Skip to main content
Clinical Trials/NCT06640764
NCT06640764
Recruiting
Not Applicable

Étude Prospective, Multicentrique, Non contrôlée, Non randomisée, Ouverte évaluant la Performance et la stabilité de l'Implant fémoral Non cimenté SMS

Medacta International SA1 site in 1 country260 target enrollmentSeptember 1, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Dysplasia of Hip Joint
Sponsor
Medacta International SA
Enrollment
260
Locations
1
Primary Endpoint
Survival rate of SMS femoral stem
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

Prospective, multicentre, non controled, non randomised, clinical study to assess the performance and the stability of SMS femoral stem

Registry
clinicaltrials.gov
Start Date
September 1, 2024
End Date
September 1, 2037
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patient suffering from a severely painful and/or disabling hip joint due to osteoarthritis, traumatic arthritis, developmental dysplasia of the hip, or avascular necrosis of the femoral head, and requiring a total hip replacement.
  • Patient who will receive a Medacta SMS femoral stem.
  • Patient agrees to comply with the study requirements.
  • Patient has signed the consent form.
  • Patient is affiliated with a social security system.
  • Patient aged 18 to 75 years

Exclusion Criteria

  • Participation in biomedical research.
  • Minor patient.
  • Protected adult patient.
  • Vulnerable individuals as defined by Article L1121-6 of the Public Health Code.
  • Pregnant or breastfeeding women.
  • Patient unable to express their non-opposition.
  • Patient refusing the collection of their personal data.
  • Acute, systemic, or chronic infection. Skeletal immaturity.
  • Grossly deformed anatomy (at the surgeon's discretion).
  • Osteomalacia for which the fixation of an uncemented implant is contraindicated.

Outcomes

Primary Outcomes

Survival rate of SMS femoral stem

Time Frame: From enrollment to the end of treatment at 10 years

Survival analysis accordin to the Kaplan-Meier method

Secondary Outcomes

  • Evaluation of the clinical performance of the SMS femoral stem(From enrollment to the end of treatment at 10 years)
  • Evaluation of the hip function(From enrollment to the end of treatment at 10 years)
  • Evaluation of the quality of life(From enrollment to the end of treatment at 10 years)
  • Evaluation of the safety (adverse events) of the SMS femoral stem(From enrollment to the end of treatment at 10 years)
  • Evaluation of the stability and the fixation of the SMS femoral stem(From enrollment to the end of treatment at 10 years)

Study Sites (1)

Loading locations...

Similar Trials